In patients with advanced refractory gastroesophageal cancer who had tried two other options, regorafenib improved overall survival when compared with placebo, offering a potential new treatment option.
Serving on an industry advisory board offers opportunities to influence clinical research, which in turn can boost an academic career, but a recent analysis found that few women have a seat at this table.
Patients with advanced pancreatic neuroendocrine tumours (NETs) have few treatment options, but researchers at Yale Cancer Center and Yale-New Haven Health s Smilow Cancer Hospital discovered that patients who received a combination of capecitabine and temozolomide had a higher progression-free survival rate than those who received temozolomide alone.